Related Experiment Video

Updated: May 30, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Receptor-tyrosine-kinase-targeted therapies for head and neck cancer

Lisa A Elferink1, Vicente A Resto

  • 1Departments of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555-1074, USA.

Journal of Signal Transduction
|July 22, 2011
PubMed

Insights

Resistance to epidermal growth factor receptor (EGFR) cancer therapy is common. Understanding cross-talk between EGFR, Met, and type 1 insulin-like growth factor receptor (IGF-1R) pathways is key to overcoming this resistance in head and neck cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Targeted therapies like those inhibiting epidermal growth factor receptor (EGFR) show promise for EGFR-expressing cancers.
  • Clinical resistance to EGFR-targeted therapies is a significant challenge, limiting their effectiveness.
  • Emerging research highlights complex signaling networks and cross-talk between receptor tyrosine kinases in cancer development.

Purpose of the Study:

  • To review the molecular interplay between EGFR, Met, and type 1 insulin-like growth factor receptor (IGF-1R) signaling pathways.
  • To elucidate the contribution of receptor cross-talk to therapeutic resistance against EGFR-directed treatments.
  • To focus on the context of squamous cell carcinoma of the head and neck, a cancer driven by EGFR signals.

Main Methods:

  • Literature review of molecular mechanisms underlying cancer signaling.
  • Analysis of receptor tyrosine kinase (RTK) cross-talk in oncogenesis.
  • Examination of resistance mechanisms in anti-EGFR therapy.

Main Results:

  • Cross-talk between EGFR, Met, and IGF-1R pathways is a critical factor in cancer.
  • This receptor interplay contributes significantly to the development of resistance to EGFR-targeted therapies.
  • Common downstream signaling pathways are activated through receptor cross-talk, bypassing direct EGFR inhibition.

Conclusions:

  • Understanding the intricate signaling network involving EGFR, Met, and IGF-1R is crucial for developing effective cancer treatments.
  • Targeting these cross-talk mechanisms may overcome resistance to current EGFR-directed therapies.
  • Further research into these interactions is warranted for improved therapeutic strategies in head and neck cancers.

More Related Videos

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...